NHS Dudley Health Economy Medicines Formulary
Home > 6 Endocrine system > 6.6 Drugs affecting bone metabolism > 6.6.2 Bisphosphonates and other drugs affecting bone metabolism > Bone metastases from solid tumours – denosumab - NICE TAG TA265

Bone metastases from solid tumours – denosumab - NICE TAG TA265

1.1 Denosumab is recommended as an option for preventing skeletal-related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from breast cancer and from solid tumours other than prostate if:

  • bisphosphonates would otherwise be prescribed and

  • the manufacturer provides denosumab with the discount agreed in the patient access scheme.

1.2 Denosumab is not recommended for preventing skeletal-related events in adults with bone metastases from prostate cancer.

1.3 Adults with bone metastases from solid tumours currently receiving denosumab for the prevention of skeletal-related events that is not recommended according to 1.1 and 1.2 should be able to continue treatment until they and their clinician consider it appropriate to stop.

 

https://www.nice.org.uk/guidance/TA265

Site by Devopa
© Copyright 2019 NHS. All rights reserved.